|Articles|March 28, 2011

HIT Press Club AJMC - Dr. A. Mark Fendrick of the University of Michigan

Dr. A Mark Fendrick welcomes the participants to the Healthcare Innovations and HIT Q&A Session at the National Press Club.

Dr. A. Mark Fendrick, editor-in-chief of The American Journal of Managed Care, welcomes the participants to the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

HIT Press Club AJMC - Dr. A. Mark Fendrick of the University of Michigan

Related Content

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD